Amgen Inc. vs Dell Technologies Inc.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Dell Technologies Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Dell Technologies Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Dell Technologies Inc. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $113.5B for Dell Technologies Inc., while their respective market capitalizations stand at $228.2B and $360.0B. Both Amgen Inc. and Dell Technologies Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Dell Technologies Inc.: Dell Technologies is one of the largest IT hardware companies in the world and, by 2026, one of the leading OEM suppliers of AI servers. It sells the laptops and desktops used by most large corporations and the servers, storage and networking that run their data centers. Founded by Michael Dell in 1984, taken private in 2013, combined with EMC in 2016 and relisted in 2018, it is now a fast-growing AI infrastructure company with a market value of roughly $360 billion in late September 2026.

Amgen Inc. and Dell Technologies Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Dell Technologies Inc..

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Dell Technologies Inc. business model: Dell makes money by selling hardware plus attached services and financing. The Infrastructure Solutions Group sells AI-optimized servers built around Nvidia (and some AMD) accelerators, traditional PowerEdge servers, networking and storage to enterprises, cloud service providers and governments; in Q2 fiscal 2027 ISG produced $31.8 billion of revenue and $4.8 billion of operating income. The Client Solutions Group sells commercial and consumer PCs, workstations and displays; Q2 fiscal 2027 CSG revenue was $15.0 billion, 88% of it commercial. Dell sells directly through its own sales force and dell.com and through channel partners, and adds recurring revenue from ProSupport warranties, deployment services, APEX subscriptions and Dell Financial Services leasing. AI servers carry thinner margins than storage or traditional servers, so Dell's profit growth depends on volume, configure-to-order supply chain efficiency and attaching higher-margin storage, networking and services.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Dell Technologies Inc..

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Dell Technologies Inc. competitive advantage: Dell's edge is breadth and scale in enterprise relationships. It can sell a customer everything from 10,000 laptops to a liquid-cooled GPU cluster with storage, networking, deployment and financing under one contract, and support it worldwide. Its configure-to-order supply chain, purchasing power with Nvidia, Intel, AMD and memory suppliers, and the 'Dell AI Factory with NVIDIA' reference designs let it ship large AI racks quickly; Dell said it had more than 4,000 AI customers by early 2026. Long-standing ownership of the commercial PC installed base also gives it a natural channel to sell AI PCs and infrastructure to the same IT buyers.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Dell Technologies Inc. each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Dell Technologies Inc. growth strategy: Dell's growth strategy has three parts. First, win AI infrastructure share by shipping GPU-dense, liquid-cooled rack systems (PowerEdge XE servers with Nvidia Blackwell-generation GPUs) to neoclouds, sovereign AI programs and large enterprises, packaged as the Dell AI Factory. Second, attach higher-margin storage (PowerScale, PowerStore, Dell's private-cloud and data-lakehouse software), networking and services to those deals. Third, capture the commercial PC refresh with the simplified Dell, Dell Pro and Dell Pro Max brands introduced in 2025 and AI PCs. Capital returns through dividends and buybacks remain part of the equity story.

A closer look at the financial trajectory of Amgen Inc. and Dell Technologies Inc. rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Dell Technologies Inc.: Dell's fiscal year ends in late January or early February. Revenue fell from $102.3 billion in fiscal 2023 to $88.4 billion in fiscal 2024 as post-pandemic PC demand faded, then recovered to $95.6 billion in fiscal 2025 and a record $113.5 billion in fiscal 2026, when net income reached $5.94 billion, operating cash flow topped $11 billion and $7.5 billion was returned to shareholders. Fiscal 2027 has accelerated: Q1 revenue was $43.8 billion (up 88%) and Q2 revenue was $47.0 billion (up 58%), with Q2 diluted EPS of $6.34. In September 2026 Dell raised full-year fiscal 2027 guidance to about $192 billion in revenue and $25.50 in non-GAAP EPS. The balance sheet still carries debt from the 2016 EMC deal, though leverage has fallen through the VMware spin-off and cash generation.